This study looks at how well elranatamab works for people with Multiple Myeloma who have already benefited from this treatment in earlier studies. Participants will receive elranatamab until their condition changes, they experience side effects, or the treatment becomes available in their country. The goal is to keep helping those who are doing well on this therapy.
The trial ID is NCT06057402. It is in Phase 4, which means it is looking at how well the treatment works and its safety. This study is regulated by the FDA and plans to include about 80 participants.
Who can join
This study is open to adults aged 18 and older. Anyone who has completed a previous study and was still receiving elranatamab is welcome to join, as long as they are benefiting from it. However, people with certain medical or mental health issues, or those who did not previously enroll in a related study, cannot participate. The trial team will confirm who is eligible.
Condition
Multiple Myeloma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive elranatamab. This treatment is a special type of antibody that helps the immune system target cancer cells. There are no random groups in this study, so all participants will receive the same treatment without any masking.
Where
This trial is enrolling at 17 locations. Recruiting sites are listed first.
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan
Recruiting
Longs Peak Hospital
Longmont, Colorado
Recruiting
St. David's South Austin Medical Center
Austin, Texas
Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida
Recruiting
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Directs the Lipper Myeloma Center, Dana-Farber. Treats multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.